High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy
- 80 Downloads
Irinotecan is effective for the treatment of metastatic colorectal cancer (mCRC) and advanced pancreatic cancer (aPC). However, these treatments are often limited due to the incidence of severe neutropenia. We identified risk factors for severe neutropenia in patients with mCRC or aPC, receiving irinotecan-based chemotherapy regimens. The study selected 104 patients (mCRC: 53 and aPC: 51) who received irinotecan-based chemotherapy between January 2014 and May 2018 and who were included in the present study. The initial dose of irinotecan was 150 mg/m2 in all patients, and patients with a lower initial dose of irinotecan were excluded. Severe neutropenia (grade ≥ 3) occurred in 56 patients (53.8%). Multivariable Cox proportional hazards analysis indicated that modified FOLFIRINOX (mFOLFIRINOX) and serum total bilirubin (T-Bil) were significant risk factors for severe neutropenia. Moreover, with receiver-operating characteristic (ROC) curve analysis, the cutoff for T-Bil was found to be 0.7 mg/dL. Among patients treated with mFOLFIRINOX therapy, the incidence of severe neutropenia was significantly higher in patients with high level of T-Bil (> 0.7 mg/dL) than in those without it (93.8% vs 55.0%, P = 0.006). A chemotherapy regimen (modified FOLFIRINOX therapy) and T-Bil > 0.7 mg/dL were significant risk factors for severe neutropenia in patients receiving 150 mg/m2 irinotecan.
KeywordsIrinotecan Severe neutropenia High level of total bilirubin Modified FOLFIRINOX Metastatic colorectal cancer Advanced pancreatic cancer
This study did not receive funding from any funding source.
Compliance with ethical standards
Conflict of interest
K Yoshida received grants, personal fees, and nonfinancial support from Chugai Pharmaceutical Co., Ltd. during the conduct of this study; grants and personal fees from Taiho Pharmaceutical Co., Ltd., Pfizer Inc., and Yakult Honsha Co., Ltd.; and grants from Bristol-Myers Squibb and Kyowa Hakko Kirin Co., Ltd. outside the submitted work. He also received honoraria from Taiho Pharmaceutical Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Yakult Honsha Co., Ltd., and had a consultant or advisory relationship with Taiho Pharmaceutical Co., Ltd. and La Roche, Ltd. T. Takahashi has received honoraria for lectures from Takeda Pharmaceutical Co., Ltd. The other authors have no conflicts of interest to disclose.
- 10.Kawato Y, Aonuma M, Matsumoto K. Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities. Gan To Kagaku Ryoho. 1991;6(6):899–907.Google Scholar
- 14.Miyata Y, Touyama T, Kusumi T, Morita Y, Mizunuma N, Taniguchi F, et al. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol. 2016;21(4):696–703.CrossRefGoogle Scholar
- 19.Negoro Y, Yano R, Watanabe K, Kayano Y, Nakamura T, Masada M, et al. Principal factors of irinotecan-induced severe neutropenia other than UGT1A1 gene polymorphism. Iryo Yakugaku. 2014;40(8):454–62.Google Scholar
- 22.Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med. 2013;4(2):627–35.Google Scholar
- 25.Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Cancer Res. 2005;11(3):1226–36.Google Scholar